Bioneer’s Combination Tests for SARS-CoV-2 and Influenza Receive CE-IVD Marking
By LabMedica International staff writers Posted on 19 Nov 2020 |
AccuPower RV1 Real-Time RT-PCR Kit (Photo courtesy of Bioneer)
Bioneer (Daejeon, Korea) has received CE-IVD marking for two combination tests for SARS-CoV-2 and influenza - the AccuPower RV1 Real-Time RT-PCR Kit and AccuPower RV1 Multiplex Kit.
The AccuPower RV1 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The 5-in-1 multiplex kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube. The user-convenient premix type kit enables pipetting free diagnosis since all the components for the assay are contained within a tube. It uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity, and the vacuum-dried premix allows for stable and reproducible results. The test kit is compatible with the ExiStation and ExiStation 48 systems.
The AccuPower RV1 Multiplex Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube and uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity. The test kit is compatible with various systems, including Exicycler 96 (BIONEER), CFX 96 (Bio-rad), ABI7500 Fast (Thermofisher), and Quantstudio 5 (Thermofisher).
The AccuPower RV1 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The 5-in-1 multiplex kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube. The user-convenient premix type kit enables pipetting free diagnosis since all the components for the assay are contained within a tube. It uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity, and the vacuum-dried premix allows for stable and reproducible results. The test kit is compatible with the ExiStation and ExiStation 48 systems.
The AccuPower RV1 Multiplex Kit is an in vitro diagnostic kit that helps diagnose COVID-19 and Influenza infections. The kit is able to detect five COVID-19 targets (E gene, RdRp & N gene) and Influenza A/B in a tube using samples collected via a nasopharyngeal swab or oropharyngeal swab taken from suspected infected patients. The easy-to-use multiplex kit reduces hands-on steps due to five-target multiplex detection in a tube and uses Bioneer’s proprietary Dual-HotStart technology to achieve high sensitivity and specificity. The test kit is compatible with various systems, including Exicycler 96 (BIONEER), CFX 96 (Bio-rad), ABI7500 Fast (Thermofisher), and Quantstudio 5 (Thermofisher).
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants